INVO earnings

Company Expects to Host Conference Call Shortly After November 20, 2023 Following the Progress of Certain Closing Conditions Pertaining to the Announced Merger Agreement with NAYA Biosciences SARASOTA, Fla., Nov. 13, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the third quarter ended September 30, 2023 and provided a business update.

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., Aug. 9, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its second quarter 2023, for the period ended June 30, 2023, after the market close on Monday, August 14, 2023. The Company has scheduled a conference call that same day, Monday, August 14, 2023, at 4:30 pm ET, to review the results.

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., May 8, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced infertility treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its first quarter 2023, for the period ended March 31, 2023, after the market close on Monday, May 15, 2023. The Company has scheduled a conference call that same day, Monday, May 15, 2023, at 4:30 pm ET, to review the results.

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., April 11, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced infertility treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its fourth quarter and fiscal year 2022, for the period ended December 31, 2022, after the market close on Monday, April 17, 2023. The Company has scheduled a conference call that same day, Monday, April 17, 2023, at 4:30 pm ET, to review the results.

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., Nov. 14, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. Q3 2022 and Recent Operational Highlights Revenue (excluding license revenue) was $235,321 compared to $40,303 in the th

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., Nov. 10, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its third quarter 2022, ended September 30, 2022, after the market close on Monday, November 14, 2022. The Company has scheduled a conference call that same day, Monday, November 14, 2022, at 4:30 pm ET, to review the results.

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., Aug. 15, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the second quarter ended June 30, 2022 and provided a business update. Recent Operational Highlights Existing INVO Centers experienced a 20% increase in patient inquiries and consultations compar

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., Aug. 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its second quarter 2022, ended June 30, 2022, after the market close on Monday, August 15, 2022. The Company has scheduled a conference call that same day, Monday, August 15, 2022, at 4:30 pm ET, to review the results.

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the first quarter ended March 31, 2022 and provided a business update. Recent Operational Highlights The three INVO Centers in Birmingham, Alabama, Atlanta, Georgia, and Monterrey, Mexico experien

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., May 9, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its first quarter 2022, ended March 31, 2022, after the market close on Monday, May 16, 2022. The Company has scheduled a conference call that same day, Monday, May 16, 2022, at 4:30 pm ET, to review the results.

Company to Host Conference Call Today at 4:30pm ET; Slide Presentation Also Available SARASOTA, Fla., March 31, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the year ended December 31, 2021, and provided a business update. Recent Operational Highlights Regained full U.S. commercialization rights to sell its INVOcel

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., March 24, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its fourth quarter and fiscal year 2021, ended December 31, 2021, after the market close on Thursday, March 31, 2022. The Company has scheduled a conference call that same day, Thursday, March 31, 2022, at 4:30 pm ET, to review the results.

SARASOTA, Fla., Nov. 9, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its third quarter 2021, ended September 30, 2021, after the market close on Monday, November 15, 2021. The Company has scheduled a conference call that same day, Monday, November 15, 2021, at 4:30 pm ET, to review the results. Third Quarter 2021 Conference Call Details Date an

SARASOTA, Fla., Aug. 16, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo culture system, today announced financial and operating results for the second quarter ended June 30, 2021 and provides a business update. Recent Operational Highlights Officially opened the first U.S.-based INVO Center, located in Birmingham, Alabama in partnership with reproductive specialists Dr. Nicholas Cataldo, MD, MPH, Dr. Karen

SARASOTA, Fla., Aug. 5, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its second quarter 2021, ended June 30, 2021, after the market close on Monday, August 16, 2021. The Company has scheduled a conference call that same day, Monday, August 16, 2021, at 4:30 pm ET, to review the results. Second Quarter 2021 Conference Call Details Date and Time: